NIKKEI 225
39,155.16 +117.00 (+0.30%) HANG SENG
18,050.60 -316.35 (-1.72%) CRUDE OIL
77.60 -0.14 (-0.18%) GOLD FUTURES
2,320.20 -6.80 (-0.29%) DOW
38,868.04 +69.05 (+0.18%) Bitcoin GBP
53,692.63 -1,061.68 (-1.94%)
ATRA Sep 2024 0.500 put
| Previous close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.2500 |
| Strike | 0.50 |
| Expiry date | 2024-09-20 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Business WireAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
THOUSAND OAKS, Calif., June 07, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 9,700 restricted stock units of Atara’s common stock to one newly hired employee. This award was approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Bio
Business WireAtara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
THOUSAND OAKS, Calif., June 05, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer and Cokey Nguyen, Ph.D., Executive Vice President, Chief Scientific & Technical Officer, will participate in a fireside chat at the Goldman Sachs 45th
Business WireAtara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
THOUSAND OAKS, Calif., May 29, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced preclinical data supporting the potential of ATA3219, an allogeneic, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy candidate for the treatment of B-cell driven autoimmune diseases. Findings demonstra
